LIFEVANTAGE CORP Lessee, Operating Lease, Liability, to be Paid, Year One
LIFEVANTAGE CORP (LFVN) had Lessee, Operating Lease, Liability, to be Paid, Year One of $2.22 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-27
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $2.22M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $2.15M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $2.16M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $2.18M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2026-06-30 | $2.22M 10-K · filed 2026-08-27 |
| 2026-03-31 | $2.15M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.16M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.21M 10-K · filed 2025-09-04 |
| 2025-03-31 | $2.33M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.31M 10-Q · filed 2025-02-05 |
| 2024-09-30 | $2.21M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $2.11M 10-K · filed 2024-08-28 |
| 2024-03-31 | $2.02M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.94M 10-Q · filed 2024-01-30 |
| 2023-09-30 | $1.94M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.92M 10-K · filed 2023-08-28 |
| 2023-03-31 | $1.93M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.93M 10-Q · filed 2023-02-02 |
| 2022-09-30 | $2.11M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $3.07M 10-K · filed 2022-08-23 |
| 2022-03-31 | $3.20M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $3.26M 10-Q · filed 2022-02-01 |
| 2021-09-30 | $3.15M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.55M 10-K · filed 2021-08-19 |
| 2021-03-31 | $2.45M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $2.43M 10-Q · filed 2021-02-02 |
| 2020-09-30 | $2.40M 10-Q · filed 2020-11-03 |
| 2020-06-30 | $1.20M 10-K · filed 2020-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |